Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

Tuija Vaananen, Katriina Vuolteenaho, Hannu Kautiainen, Riina Nieminen, Timo Mottonen, Pekka Hannonen, Markku Korpela, Markku J. Kauppi, Kari Laiho, Oili Kaipiainen-Seppanen, Riitta Luosujarvi, Tea Uusitalo, Toini Uutela, Marjatta Leirisalo-Repo, Eeva Moilanen, NEO-RACo Study Grp

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
Article number0183294
JournalPLoS One
Volume12
Issue number8
Number of pages15
ISSN1932-6203
DOIs
Publication statusPublished - 25 Aug 2017
MoE publication typeA1 Journal article-refereed

Fields of Science

  • HUMAN CARTILAGE GLYCOPROTEIN-39
  • SERUM YKL-40
  • RADIOGRAPHIC PROGRESSION
  • COMBINATION THERAPY
  • PERIPHERAL-BLOOD
  • ACTIVITY SCORES
  • FOLLOW-UP
  • MHC CLASS
  • JOINT
  • INFLAMMATION
  • 3121 Internal medicine
  • 3111 Biomedicine

Cite this

Vaananen, T., Vuolteenaho, K., Kautiainen, H., Nieminen, R., Mottonen, T., Hannonen, P., Korpela, M., Kauppi, M. J., Laiho, K., Kaipiainen-Seppanen, O., Luosujarvi, R., Uusitalo, T., Uutela, T., Leirisalo-Repo, M., Moilanen, E., & NEO-RACo Study Grp (2017). Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS One, 12(8), [0183294]. https://doi.org/10.1371/journal.pone.0183294